-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AL-1211 in Gaucher Disease Type I
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AL-1211 in Gaucher Disease Type I report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AL-1211 in Gaucher Disease Type I Drug Details: AL-1...
-
Product Insights
NewNet Present Value Model: Celldex Therapeutics Inc’s Barzolvolimab
Empower your strategies with our Net Present Value Model: Celldex Therapeutics Inc's Barzolvolimab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Varlilumab in Mantle Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Varlilumab in Mantle Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Varlilumab in Mantle Cell Lymphoma Drug Details: Varlilumab (CDX-1127) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Varlilumab in Marginal Zone B-cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Varlilumab in Marginal Zone B-cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Varlilumab in Marginal Zone B-cell Lymphoma Drug Details: Varlilumab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CDX-301 in Skin Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CDX-301 in Skin Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CDX-301 in Skin Cancer Drug Details: CDX-301 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CDX-301 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CDX-301 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CDX-301 in Triple-Negative Breast Cancer (TNBC) Drug Details: CDX-301...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Barzolvolimab in Prurigo
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Barzolvolimab in Prurigo report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Barzolvolimab in Prurigo Drug Details: Barzolvolimab (CDX-0159) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Barzolvolimab in Chronic Urticaria Or Hives
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Barzolvolimab in Chronic Urticaria Or Hives report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Barzolvolimab in Chronic Urticaria Or Hives Drug Details: Barzolvolimab...
-
Innovation Ranking
Innovation Ranking – Celldex Therapeutics Inc
Celldex Therapeutics Inc (Celldex) is a bio-pharmaceutical company that discovers, develops, and commercializes targeted immunotherapy and other biologics for the treatment of various types of cancers. The company’s developmental pipeline comprises therapeutic antibodies, antibody drug conjugates (ADCs), protein-based therapeutics, immune system modulators and vaccine for unmet medical needs. Its key products in development include CDX-1140; CDX-527, CDX-0159. Celldex’s products find application in the treatment of various indications such as brain cancer, triple negative breast cancer, lymphoma/leukemia, melanoma, and renal cell...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Varlilumab in Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Varlilumab in Glioblastoma Multiforme (GBM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Varlilumab in Glioblastoma Multiforme (GBM) Drug Details: Varlilumab (CDX-1127) is under...